Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 24;14(12):570-583.
doi: 10.5306/wjco.v14.i12.570.

Update on current diagnosis and management of anaplastic thyroid carcinoma

Efstathios T Pavlidis  1 , Ioannis N Galanis  1 , Theodoros E Pavlidis  2
Affiliations
Review

Update on current diagnosis and management of anaplastic thyroid carcinoma

Efstathios T Pavlidis et al. World J Clin Oncol. .

Abstract

Well-differentiated thyroid carcinoma has a favorable prognosis with a 5-year survival rate of over 95%. However, the undifferentiated or anaplastic type accounting for < 0.2%, usually in elderly individuals, exhibits a dismal prognosis with rapid growth and disappointing outcomes. It is the most aggressive form of thyroid carcinoma, with a median survival of 5 mo and poor quality of life (airway obstruction, dysphagia, hoarseness, persistent pain). Early diagnosis and staging are crucial. Diagnostic tools include biopsy (fine needle aspiration, core needle, open surgery), high-resolution ultrasound, computed tomography, magnetic resonance imaging, [(18)F]fluoro-D-glucose positron emission tomo-graphy/computed tomography, liquid biopsy and microRNAs. The BRAF gene (BRAF-V600E and BRAF wild type) is the most often found molecular factor. Others include the genes RET, KRAS, HRAS, and NRAS. Recent management policy is based on surgery, even debulking, chemotherapy (cisplatin or doxorubicin), radiotherapy (adjuvant or definitive), targeted biological agents and immunotherapy. The last two options constitute novel hopeful management modalities improving the overall survival in these otherwise condemned patients. Anti-programmed death-ligand 1 antibody immunotherapy, stem cell targeted therapies, nanotechnology achievements and artificial intelligence imple-mentation provide novel promising alternatives. Genetic mutations determine molecular pathways, thus indicating novel treatment strategies such as anti-BRAF, anti-vascular endothelial growth factor-A, and anti-epidermal growth factor receptor. Treatment with the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has been approved by the Food and Drug Administration in cases with BRAF-V600E gene mutations and is currently the standard care. This neoadjuvant treatment followed by surgery ensures a two-year overall survival of 80%. Prognostic factors for improved outcomes have been found to be younger age, earlier tumor stage and radiation therapy. A multidisciplinary approach is necessary, and the therapeutic plan should be individualized based on surveillance and epidemiology end results.

Keywords: Aggressive malignancies; Anaplastic carcinoma; Neck mass; Thyroid cancers; Thyroid diseases; Undifferentiated carcinoma.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Figures

Figure 1
Figure 1
Scheme of diagnostic steps for anaplastic thyroid carcinoma. CT: Computed tomography; MRI: Magnetic resonance imaging; PET-CT: Positron emission tomography/computed tomography; TNM: Tumor-node-metastasis.
Figure 2
Figure 2
Scheme of treatment steps for resectable anaplastic thyroid carcinoma.
Figure 3
Figure 3
Scheme of treatment steps for unresectable anaplastic thyroid carcinoma.
See this image and copyright information in PMC

References

    1. Pereira M, Williams VL, Hallanger Johnson J, Valderrabano P. Thyroid Cancer Incidence Trends in the United States: Association with Changes in Professional Guideline Recommendations. Thyroid. 2020;30:1132–1140. - PubMed
    1. Mirian C, Grønhøj C, Jensen DH, Jakobsen KK, Karnov K, Jensen JS, Hahn CH, Klitmøller TA, Bentzen J, von Buchwald C. Trends in thyroid cancer: Retrospective analysis of incidence and survival in Denmark 1980-2014. Cancer Epidemiol. 2018;55:81–87. - PubMed
    1. Janz TA, Neskey DM, Nguyen SA, Lentsch EJ. Is the incidence of anaplastic thyroid cancer increasing: A population based epidemiology study. World J Otorhinolaryngol Head Neck Surg. 2019;5:34–40. - PMC - PubMed
    1. Califano I, Smulever A, Jerkovich F, Pitoia F. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease. Rev Endocr Metab Disord. 2023 - PubMed
    1. de Ridder M, Nieveen van Dijkum E, Engelsman A, Kapiteijn E, Klümpen HJ, Rasch CRN. Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades. Eur J Endocrinol. 2020;183:203–209. - PubMed